Search | Clinical Trials Finder

Conditions: Mild Cognitive Impairment
Interventions: Cognitive training, Nutrition; Behavioral · Dietary Supplement
Lead sponsor: Gibson Institute of Cognitive Research; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV; Drug
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Sinusitis, Cystic Fibrosis
Interventions: Pulmozyme single use ampule, placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myeloid Leukemia, Monocytic Leukemia
Interventions: Venetoclax, Azacitidine, Mitoxantrone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder
Interventions: Spironolactone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 13 Years to 19 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Parkinson Disease, Idiopathic Parkinson Disease
Interventions: N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography; Dietary Supplement · Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 30 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Interventions: Azacitidine Subcutaneous Injection or Intravenous Infusion, Pevonedistat Infusion, Bone Marrow Biopsy & Aspirate; Drug · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Miami, Florida • Westwood, Kansas • New York, New York + 2 more

Conditions: Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions: ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm; Biological · Other
Lead sponsor: Jay S. Skyler; Other
Eligibility: 8 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions: Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 39
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Conditions: Alcohol Use Disorder
Interventions: Exenatide, Sham injection; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Knee, Pain, Nerve; Lesion
Interventions: genicular nerve diagnostic block with lidocaine (local anesthetic), genicular nerve radiofrequency ablation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Dupilumab SAR231893; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Cystic Fibrosis
Interventions: LUM/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Months and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more

Conditions: Firearm Injury, Hospitalizations Psychiatric
Interventions: Guardians receiving counseling + lock; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sexually Transmitted Infections, HIV Infections
Interventions: Experimental; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions: Topical niacinamide 5% cream, Sunscreen; Drug
Lead sponsor: Marissa Lobl; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Premature Ventricular Beats
Interventions: Ranolazine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pompe Disease
Interventions: Duvoglustat; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Major Depressive Disorder
Interventions: Ixekizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Overweight
Interventions: Choices; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 8 Years to 11 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rattlesnake Envenomation
Interventions: Ketamine, Fentanyl; Drug
Lead sponsor: Meghan Spyres; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Multidisciplinary Intervention for Mild Cognitive Impairment

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Pulmozyme in Cystic Fibrosis With Sinusitis

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?

FDOPA PET and Nutritional Support in Parkinson's Disease

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Low-dose IL-2 in Established T1D - The "PROREG" Study

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Diagnostic Genicular Nerve Block Prior to Radiofrequency Ablation for Knee Osteoarthritis Pain

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Safer Storage Safer Homes An Inpatient Pediatric Lethal Means Counseling Pilot Trial

A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Study to Reduce Symptoms of Premature Beats With Ranolazine

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

Targeting IL-17A for Treatment-Resistant Depression

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

CHOICES: Family Physicians Treat Overweight Children

Ketamine Pilot Study